Evidence map›Paper›PMID 24513692›Full record

Trial reportThe pharmacogenomics journal2014

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).

A Chhibber, J Mefford, E A Stahl, S A Pendergrass, R M Baldwin, K Owzar, M Li, E P Winer, C A Hudis, H Zembutsu and 9 more

Open access · greenAbstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 2 countries.

A Chhibber1] Departments of Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA [2] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA.
J Mefford1] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA [2] Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, USA.
E A Stahl1] Division of Rheumatology, Immunology, and Allergy, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA [2] Medical and Population Genetics Program, Chemical Biology Program, Broad Institute, Cambridge, MA, USA.
S A PendergrassCenter for Systems Genomics, Department of Biochemistry and Molecular Biology, The Pennsylvania State University, Eberly College of Science, The Huck Institutes of the Life Sciences, University Park, PA, USA.
R M Baldwin1] Departments of Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA [2] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA.
K OwzarAlliance Statistics and Data Center, Duke University Medical Center, Durham, NC, USA.
M Li1] Departments of Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA [2] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA.
E P WinerDana-Farber Cancer Institute, Boston, MA, USA.
C A HudisMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
H ZembutsuLaboratory of Molecular Medicine, University of Tokyo, Tokyo, Japan.
M KuboCenter for Integrative Medical Sciences, Riken Center, Yokohama, Japan.
Y Nakamura1] Laboratory of Molecular Medicine, University of Tokyo, Tokyo, Japan [2] Center for Integrative Medical Sciences, Riken Center, Yokohama, Japan [3] Department of Medicine, University of Chicago, Chicago, IL, USA.
H L McLeodDepartment of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
M J RatainDepartment of Medicine, University of Chicago, Chicago, IL, USA.
L N ShulmanDana-Farber Cancer Institute, Boston, MA, USA.
M D RitchieCenter for Systems Genomics, Department of Biochemistry and Molecular Biology, The Pennsylvania State University, Eberly College of Science, The Huck Institutes of the Life Sciences, University Park, PA, USA.
R M Plenge1] Division of Rheumatology, Immunology, and Allergy, Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA [2] Medical and Population Genetics Program, Chemical Biology Program, Broad Institute, Cambridge, MA, USA.
J S Witte1] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA [2] Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, USA.
D L Kroetz1] Departments of Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA [2] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USDana-Farber Cancer Institute · USPennsylvania State University · USThe University of Tokyo · JPBrigham and Women's Hospital · USBroad Institute · USDuke Medical Center · USMemorial Sloan Kettering Cancer Center · USRIKEN Center for Integrative Medical Sciences · JPUniversity of Chicago · USUniversity of North Carolina at Chapel Hill · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
Whole GenomeU01GM061393 · NIGMS · UNIVERSITY OF CHICAGO · PI COX, NANCY J, DOLAN, MARY EILEEN · 2000 to 2014
$39.0M
PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
PHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KWOK, PUI-YAN · 2010 to 2014
$16.3M
PHARMACEUTICAL SCIENCES AND PHARMACOGENOMICST32GM007175 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, KROETZ, DEANNA L · 1985 to 2021
$7.1M
NCTN Lead Academic Participating Sites ApplicationU10CA180838 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAREY, LISA A · 2014 to 2018
$2.8M
NCI NIH HHS CA31946NCI NIH HHS P30 CA014236NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA180838NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U19 HL065962NIGMS NIH HHS T32 GM007175NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U01 GM061393NIGMS NIH HHS U01 GM61390NIGMS NIH HHS U01 GM61393NIGMS NIH HHS U19 GM061390
6 · The paper itself

Abstract

Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that predispose patients to the adverse event, and pathogenesis for paclitaxel-induced peripheral neuropathy is unknown. Determining whether there is a heritable component to paclitaxel-induced peripheral neuropathy would be valuable in guiding clinical decisions and may provide insight into treatment of and mechanisms for the toxicity. Using genotype and patient information from the paclitaxel arm of CALGB 40101 (Alliance), a phase III clinical trial evaluating adjuvant therapies for breast cancer in women, we estimated the variance in maximum grade and dose at first instance of sensory peripheral neuropathy. Our results suggest that paclitaxel-induced neuropathy has a heritable component, driven in part by genes involved in axon outgrowth. Disruption of axon outgrowth may be one of the mechanisms by which paclitaxel treatment results in sensory peripheral neuropathy in susceptible patients.

Indexed as

Multifactorial InheritanceAntineoplastic Agents, PhytogenicAxonsBreast NeoplasmsFemaleHumansPaclitaxelPeripheral Nervous System DiseasesPolymorphism, Single NucleotideSensory Receptor CellsAntineoplastic Agents, PhytogenicPaclitaxel

Identifiers

PMID24513692
PMCPMC4111770
OpenAlexW2112546872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.